Agios Pharmaceuticals Touts Mitapivat Gains Despite Sickle Cell Pain Miss
Agios reported encouraging mitapivat data in thalassemia, saying long-term extension results from ENERGIZE showed durable hemoglobin responses and no new safety concerns.
Agios reported encouraging mitapivat data in thalassemia, saying long-term extension results from ENERGIZE showed durable hemoglobin responses and no new safety concerns.